A huge financial burden is imposed due to deaths caused by Inflammatory lung diseases. Treatment of inflammatory lung diseases can be targeted via the lungs because of their unique features. Inhalation therapy can target them with the help of inhaled therapy. This Research aims to present the wide-ranging role of nanoemulsions in treating inflammatory respiratory diseases by increasing the solubility of BCS class II drugs. Our target was to enhance the solubility of Ivacaftor, which belongs to a class of CFTR potentiators and a BCS class II drug. The solubility enhancement was to be achieved with the help of formulation into a nanoemulsion. Nanoemulsion has the advantage of being a thermodynamically stable formulation. We used Tween 20 as a surfactant and Transcutol-p as a co-surfactant. The region of the emulsion was identified after the construction of a pseudo-ternary phase diagram. The formulation was optimized using Design Expert 13, and the final preparation was evaluated for stability. The final formulation gave a globule size of 97.65±0.52 nm and a zeta potential of -1.75±0.46mV. The FTIR spectra showed very minimal changes keeping the peaks of the drug intact. We found the formulations were stable after a one-month stability study. Biological barriers in the human body can be overcome by utilizing nanoemulsions to achieve quicker onset of action and immediate relief. Inhaled nanocarriers pose a potential regarding translational studies and increase the scientific database for managing inflammatory lung diseases with reduced or no toxicity.